Founded by Altius Bioventures Capital, SPV2 B.V. develops next-generation rapid QC testing assays designed to operate on Biocartis’ proven Idylla™ platform. By leveraging this robust and de-risked qPCR diagnostic system, SPV2 brings reliable and scalable quality control solutions to the bioproduction industry.
Headquartered in the Netherlands, SPV2’s platform enables rapid, decentralized, and cost-effective QC testing for cell and gene therapies, biologics, and vaccine manufacturing.
SPV2’s first product—the Idylla™ Mycoplasma assay—is purpose-built for cell therapy, biologics, and pandemic-scale vaccine production, providing rapid and reliable testing in both centralized and decentralized settings.
While manufacturing technologies in CGT have advanced, quality control testing has lagged behind, often requiring dedicated PCR labs with multimillion-dollar infrastructure, skilled FTEs performing complex workflows, and high CoGs, limiting patient access.
SPV2 is addressing this quality control challenge by adapting the Idylla™ platform from Biocartis—a proven, fully automated benchtop PCR system widely used in clinical diagnostics—to meet the specific and evolving needs of Cell and Gene Therapy developers.
Our first product is a rapid analytical mycoplasma testing cartridge, purpose-built for the unique demands of cell therapy manufacturing environments. With minimal hands-on time and no protocol development required, the system enables push-button testing with a rapid turnaround and robust performance. The company’s broader strategy is to expand its Idylla™ applications across CGT, vaccines and other biologics, making automated QC testing universally accessible.
This opportunity stands out because the rapid analytical testing technology is already mature, the proof-of-concept is compelling, and the demand for improved quality control in cell and gene therapy is both urgent and growing.
If you're interested in learning more or exploring participation in this vehicle, we’d be happy to start the conversation. Please reach out to our CEO or connect with Emmanuel at Altius.
Copyright © 2025 Altius Bioventures Capital - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.